NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free NKTR Stock Alerts $1.32 -0.06 (-4.35%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.29▼$1.3750-Day Range$0.66▼$1.6752-Week Range$0.41▼$1.75Volume1.05 million shsAverage Volume2.15 million shsMarket Capitalization$242.38 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Nektar Therapeutics alerts: Email Address Nektar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside165.2% Upside$3.50 Price TargetShort InterestHealthy1.75% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.00Based on 5 Articles This WeekInsider TradingSelling Shares$19,752 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.93) to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.53 out of 5 starsMedical Sector201st out of 907 stocksPharmaceutical Preparations Industry79th out of 422 stocks 3.0 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.75% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently increased by 31.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 5 news articles for Nektar Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,752.00 in company stock.Percentage Held by InsidersOnly 3.07% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Nektar Therapeutics Stock (NASDAQ:NKTR)Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Read More NKTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTR Stock News HeadlinesApril 24, 2024 | globenewswire.comBiolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune DiseasesApril 24, 2024 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Hold" by AnalystsApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 20, 2024 | finance.yahoo.comNatural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline DrugsApril 20, 2024 | investing.comNektar regains Nasdaq compliance with bid priceApril 16, 2024 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Stock Price Passes Above Two Hundred Day Moving Average of $0.65April 10, 2024 | seekingalpha.comNektar Therapeutics Sees Something In The Data And Puts Its Drug To The TestMarch 29, 2024 | yahoo.com“A fascinating listen that sometimes sounds like a missing 10cc album plus a little Be Box Deluxe”: Nektar’s Recycled 5CD setApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 22, 2024 | prnewswire.comNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 5, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | finance.yahoo.comQ4 2023 Nektar Therapeutics Earnings CallMarch 5, 2024 | prnewswire.comNektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataMarch 4, 2024 | markets.businessinsider.comNektar Therapeutics Q4 Loss decreases, but misses estimatesMarch 4, 2024 | finance.yahoo.comNektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 ResultsMarch 4, 2024 | prnewswire.comNektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsMarch 4, 2024 | markets.businessinsider.comNektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In PremarketMarch 4, 2024 | prnewswire.comNektar Therapeutics Announces $30 Million Private Placement Financing with TCGXMarch 3, 2024 | markets.businessinsider.comNektar Therapeutics earnings: here's what Wall Street expectsMarch 1, 2024 | benzinga.comNektar Therapeutics Earnings PreviewFebruary 27, 2024 | prnewswire.comNektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 26, 2024 | prnewswire.comNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsFebruary 23, 2024 | msn.comNektar to play final UK live show at Nene Valley Rock festival in SeptemberFebruary 22, 2024 | msn.comEuro zone bond yields dip, data shows wage growth slowed in Q4February 22, 2024 | benzinga.comNektar Therapeutics Stock (NASDAQ:NKTR) Insider TradesFebruary 20, 2024 | finance.yahoo.comWill Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should KnowJanuary 22, 2024 | finance.yahoo.comDiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical OfficerSee More Headlines Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees137Year Founded1990Price Target and Rating Average Stock Price Target$3.50 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+168.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,060,000.00 Net Margins-306.31% Pretax Margin-306.54% Return on Equity-96.80% Return on Assets-37.17% Debt Debt-to-Equity RatioN/A Current Ratio6.45 Quick Ratio6.14 Sales & Book Value Annual Sales$90.12 million Price / Sales2.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book1.89Miscellaneous Outstanding Shares183,620,000Free Float177,981,000Market Cap$239.62 million OptionableOptionable Beta0.90 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Howard W. Robin (Age 71)CEO, President & Director Comp: $1.83MMr. Mark A. Wilson (Age 52)Senior VP, Chief Legal Officer & Secretary Comp: $749.99kDr. Jonathan Zalevsky Ph.D. (Age 49)Chief Research & Development Officer Comp: $1.25MMs. Sandra A. Gardiner (Age 58)Interim Chief Financial Officer Vivian WuDirector of Investor Relations & Corporate AffairsMr. Robert BacciSenior Vice President of Human Resources & Facilities OperationsMs. Jennifer RuddockChief Business OfficerDr. Mary Tagliaferri L.Ac. (Age 58)M.D., Chief Medical Officer More ExecutivesKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIROmerosNASDAQ:OMERSeres TherapeuticsNASDAQ:MCRBADC TherapeuticsNYSE:ADCTAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 778,967 shares on 4/24/2024Ownership: 0.919%Howard W RobinSold 20,033 sharesTotal: $13,622.44 ($0.68/share)Jonathan ZalevskySold 9,014 sharesTotal: $6,129.52 ($0.68/share)GSA Capital Partners LLPBought 3,414,712 shares on 2/16/2024Ownership: 2.755%Public Employees Retirement System of OhioSold 35,200 shares on 2/16/2024Ownership: 0.144%View All Insider TransactionsView All Institutional Transactions NKTR Stock Analysis - Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares. View NKTR analyst ratings or view top-rated stocks. What is Nektar Therapeutics' stock price target for 2024? 5 analysts have issued 12-month price targets for Nektar Therapeutics' shares. Their NKTR share price targets range from $1.00 to $6.00. On average, they expect the company's share price to reach $3.50 in the next year. This suggests a possible upside of 165.2% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. How have NKTR shares performed in 2024? Nektar Therapeutics' stock was trading at $0.5650 on January 1st, 2024. Since then, NKTR shares have increased by 133.6% and is now trading at $1.32. View the best growth stocks for 2024 here. Are investors shorting Nektar Therapeutics? Nektar Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 3,110,000 shares, an increase of 31.8% from the March 31st total of 2,360,000 shares. Based on an average trading volume of 2,440,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 1.8% of the shares of the stock are sold short. View Nektar Therapeutics' Short Interest. When is Nektar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our NKTR earnings forecast. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.01. The biopharmaceutical company earned $23.89 million during the quarter, compared to analyst estimates of $17.09 million. Nektar Therapeutics had a negative net margin of 306.31% and a negative trailing twelve-month return on equity of 96.80%. During the same quarter last year, the business posted ($0.32) earnings per share. What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.92%). Insiders that own company stock include Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NKTR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
